Incidence and Prevalence of Chronic Spontaneous Urticaria Among Adult and Pediatric Populations in the United States

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-04-16 DOI:10.1007/s12325-025-03172-0

Yvonne Geissbühler, Maria M. Balp, Aine McConnon, Justin Gomme, Sarah J. McKenna, Ravneet K. Kohli, Weily Soong

{"title":"Incidence and Prevalence of Chronic Spontaneous Urticaria Among Adult and Pediatric Populations in the United States","authors":"Yvonne Geissbühler, Maria M. Balp, Aine McConnon, Justin Gomme, Sarah J. McKenna, Ravneet K. Kohli, Weily Soong","doi":"10.1007/s12325-025-03172-0","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Published evidence on the epidemiology of chronic spontaneous urticaria (CSU) in the USA is limited. This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.</p><h3>Methods</h3><p>The target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan. The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart. The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017. In Optum EHR the incidence rate and prevalence were standardized by age and sex as compound strata and by age (adult and pediatric populations separately), and in both Optum CDM and MarketScan, data was standardized by sex as a single stratum of adult and pediatric populations. The age- and sex-standardized incidence rate and prevalence were calculated and reported per 100 person-years and per 100 persons (%), respectively.</p><h3>Results</h3><p>A total of 108,384 patients (adults, 72.1%; pediatric patients, 27.9%) from Optum EHR, 107,682 (adults, 78.5%; pediatric patients, 21.5%) from Optum CDM, and 278,311 (adults, 63.5%; pediatric patients, 36.5%) from MarketScan were identified with CSU diagnosis during the identification period. The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012–2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively. The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012–2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively. The sex-standardized combined (adult and pediatric) incidence rate and prevalence were 0.096 per 100 person-years and 0.283%, respectively. The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012–2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively. The sex-standardized combined (adult and pediatric) incidence rate and prevalence were 0.088 per 100 person-years and 0.244%, respectively.</p><h3>Conclusion</h3><p>The findings of this study highlight a general increasing trend in the incidence and prevalence of diagnosed CSU over time among the US population. Comparatively, the incidence and prevalence were higher among pediatric patients than adults.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2808 - 2820"},"PeriodicalIF":3.4000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03172-0.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03172-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Published evidence on the epidemiology of chronic spontaneous urticaria (CSU) in the USA is limited. This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.

Methods

The target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan. The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart. The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017. In Optum EHR the incidence rate and prevalence were standardized by age and sex as compound strata and by age (adult and pediatric populations separately), and in both Optum CDM and MarketScan, data was standardized by sex as a single stratum of adult and pediatric populations. The age- and sex-standardized incidence rate and prevalence were calculated and reported per 100 person-years and per 100 persons (%), respectively.

Results

A total of 108,384 patients (adults, 72.1%; pediatric patients, 27.9%) from Optum EHR, 107,682 (adults, 78.5%; pediatric patients, 21.5%) from Optum CDM, and 278,311 (adults, 63.5%; pediatric patients, 36.5%) from MarketScan were identified with CSU diagnosis during the identification period. The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012–2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively. The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012–2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively. The sex-standardized combined (adult and pediatric) incidence rate and prevalence were 0.096 per 100 person-years and 0.283%, respectively. The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012–2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively. The sex-standardized combined (adult and pediatric) incidence rate and prevalence were 0.088 per 100 person-years and 0.244%, respectively.

Conclusion

The findings of this study highlight a general increasing trend in the incidence and prevalence of diagnosed CSU over time among the US population. Comparatively, the incidence and prevalence were higher among pediatric patients than adults.

查看原文本刊更多论文

慢性自发性荨麻疹在美国成人和儿童人群中的发病率和患病率。

美国发表的关于慢性自发性荨麻疹（CSU）流行病学的证据是有限的。本研究旨在估计美国人群中年龄和/或性别标准化的CSU发病率和患病率。方法：使用三个匿名数据库确定目标人群：Optum电子健康记录（EHR）、Optum临床数据集市（CDM）和Truven健康市场扫描。研究人群包括成人（年龄≥18岁）和儿童（年龄≥18岁）。结果：共108,384例患者(成人，72.1%；来自Optum EHR的107,682名儿童患者，27.9%（成人，78.5%）；来自Optum CDM的儿科患者占21.5%,278,311例(成人占63.5%；来自MarketScan的儿童患者（36.5%）在鉴定期间被诊断为CSU。确认期间（2012-2018年），Optum EHR中成人和儿童确诊CSU的年龄和性别标准化发病率分别为0.039和0.066 / 100人-年，患病率分别为0.120%和0.193%。Optum CDM（2012-2018）中成人和儿童确诊CSU的年龄标准化发病率分别为0.094和0.109 / 100人-年，患病率分别为0.277%和0.304%。性别标准化合并（成人和儿童）发病率和患病率分别为0.096 / 100人-年和0.283%。MarketScan（2012-2017）中成人和儿童确诊CSU的年龄标准化发病率分别为0.102和0.097 / 100人-年，患病率分别为0.256%和0.264%。性别标准化合并（成人和儿童）发病率和患病率分别为0.088 / 100人-年和0.244%。结论：这项研究的结果强调了美国人群中诊断的CSU的发病率和患病率随着时间的推移呈总体上升趋势。相比之下，儿童患者的发病率和患病率高于成人。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.